CoChat

The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index; 23 of the 57 sources its claims cite were checked for support.

Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review

Open access
Feier, Catalin, Vonica, Razvan, Faur, Alaviana, Streinu, Diana, Muntean, Calin · 2024 · International Journal of Molecular Sciences

Abstract

Systematic review of 10 RCTs (14,550 participants) assessing thyroid cancer risk and adverse events of semaglutide. Thyroid cancer incidence less than 1%, suggesting no significant risk. GI symptoms predominant: nausea (2.05-19.95%), diarrhea (1.4-13%).

Overview

CoChat Summary

TL;DR

This systematic review pooled 10 randomized controlled trials of semaglutide involving 14,550 participants and found thyroid cancer incidence to be very low, with reported cases each under 1% in the relevant study groups. The main adverse events were gastrointestinal, especially nausea and diarrhea, while the review found no significant evidence of a thyroid carcinogenic signal for semaglutide.

Key findings

  • The final analysis included 10 RCTs published from 2016 to 2022, with 14,550 patients total and 7,830 receiving semaglutide.
  • Across the included studies, thyroid cancer incidence was less than 1%, with only isolated cases of papillary thyroid cancer and medullary thyroid cancer reported.
  • Reported adverse events were mainly gastrointestinal: nausea ranged from 2.05% to 19.95%, diarrhea from 1.4% to 13%, and average prevalences included nasopharyngitis 8.23%, vomiting 5.97%, headaches 7.92%, constipation 6.91%, and dyspepsia 5.18%.
  • Serious adverse events ranged from 7% to 25.2%; among semaglutide-treated patients across 29 studies, there were 320 severe hypoglycemia cases (3.47%), 18 AKI cases (0.20%), and 22 pancreatitis cases (0.24%).

Methods

  • Systematic review following PRISMA; searches were conducted in PubMed, Scopus, and Embase up to December 2023, using semaglutide/thyroid cancer/safety-related terms.
  • Included human, peer-reviewed English studies on semaglutide in patients with diabetes and/or obesity that reported thyroid cancer incidence and/or adverse events; excluded non-human, grey literature, and studies without relevant outcomes.
  • Quality/risk of bias for observational studies was assessed with the Newcastle–Ottawa Scale; screening and quality assessment were done independently by two reviewers with a third reviewer for disagreements.

Limitations

  • The paper states that post-marketing and real-world use were not covered, so delayed adverse outcomes could not be assessed.
  • The studies were highly variable, making a funnel plot analysis for publication bias impossible and the outcome reporting too non-uniform to conduct a meta-analysis effectively.
  • Evident from the text: the synthesis relied on RCTs and selected reported outcomes, so very rare events and longer-term risks may be underpowered or incompletely captured.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms25084346

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA flow diagram.
Figure 1 PRISMA flow diagram.CC BY · PubMed Central
Figure 2 Aggregate mean values with adverse events and complications across all studies after semaglutide use.
Figure 2 Aggregate mean values with adverse events and complications across all studies after semaglutide use.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 4 Not valid · 15 Not checked · 26 Own results and interpretations

29 more claims · 6 with their cited sources checked

Create a free account to see all 56 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 15
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. (2024, February 15). Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment) [Internet], Available online: https://www.ncbi.nlm.nih.gov/books/NBK544016/.

Cited by

See all 61

Metadata

Authors
Feier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C.
Affiliations
  • First Discipline of Surgery, Department X-Surgery, “Victor Babes” University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania
  • Lucian Blaga University of Sibiu (RO)
  • Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
  • Medical Informatics and Biostatistics, Department III-Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania
Corresponding author
Vonica, Razvan
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-04-15
Volume
25
Issue
8
Pages
4346
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4394821829
Cited by
60
References
54
Citations by year
2026: 18 · 2025: 35 · 2024: 8
FWCI
5.83
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
Funders
“Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
semaglutide, GLP-1 receptor agonists, thyroid cancer risk, drug safety, adverse events, gastrointestinal adverse effects, nausea, diarrhea
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Diabetes Mellitus, Type 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. https://app.cochat.ai/papers/10.3390/ijms25084346
The paper
Feier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C. (2024). Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084346

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.